Kup-101a

Phase 1

KKupando GmbH

Kup-101a is one of 33 therapeutic programs targeting Cutaneous Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cutaneous MelanomaRecruiting

Cutaneous MelanomaPhase 1

Recruiting

Competition

Competitive Landscape

33 competitors in Cutaneous Melanoma

#DrugCompanyPhaseTrials

Koselugo

Thalomid

Bayer Aspirin

Afinitor

Fludara

Plaquenil

Cotellic

Calciferol

Alkeran

1 10

Tasigna

AAzurity Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Cutaneous Melanoma

NCT07600476

Clinical

Trials by Indication[1]

Cutaneous Melanoma1 trial

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Recruiting·KKupando GmbH·Phase 1·NCT07600476·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kup-101a. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Kup-101a. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kupando GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: KKupando GmbH

Kup-101a

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News